生产(经济)
订单(交换)
业务
风险分析(工程)
经济
财务
宏观经济学
标识
DOI:10.1016/j.beha.2018.01.002
摘要
The clinical success achieved using CD19-directed CAR-T cells has stimulated many academic institutions to explore the feasibility of manufacturing these, and other CAR-T cells, in-house. This article reviews the issues that must be addressed in order to achieve this goal. It includes the manufacturing infrastructure, the regulatory environment, practical aspects of production, and the costs involved.
科研通智能强力驱动
Strongly Powered by AbleSci AI